Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pul...
Verona Pharma reported revenue of $42.28 million for fiscal year 2024, and net income of -$173.42 million. In Q2 2025 (the quarter ended June 30, 2025) revenue was $103.14 million.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.